West Pharmaceutical Services (WST) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WST shares.
View WST analyst ratings or view top-rated stocks.

5 analysts have issued 12 month price objectives for West Pharmaceutical Services' shares. Their WST share price forecasts range from $250.00 to $440.00. On average, they anticipate the company's share price to reach $361.00 in the next twelve months. This suggests that the stock has a possible downside of 4.8%.
View analysts price targets for WST or view top-rated stocks among Wall Street analysts.

West Pharmaceutical Services' stock was trading at $235.35 on January 1st, 2023. Since then, WST stock has increased by 61.1% and is now trading at $379.23.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our WST earnings forecast.

West Pharmaceutical Services, Inc. (NYSE:WST) issued its earnings results on Thursday, July, 27th. The medical instruments supplier reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.16. The medical instruments supplier had revenue of $753.80 million for the quarter, compared to analyst estimates of $755.71 million. West Pharmaceutical Services had a trailing twelve-month return on equity of 22.36% and a net margin of 18.10%. The business's revenue was down 2.3% compared to the same quarter last year. During the same period last year, the firm earned $2.47 earnings per share.
Read the conference call transcript.

West Pharmaceutical Services declared a quarterly dividend on Thursday, April 27th. Stockholders of record on Wednesday, July 26th will be paid a dividend of $0.19 per share on Wednesday, August 2nd. This represents a $0.76 dividend on an annualized basis and a yield of 0.20%. The ex-dividend date is Tuesday, July 25th.
Read our dividend analysis for WST.

ETFs with the largest weight of West Pharmaceutical Services (NYSE:WST) stock in their portfolio include Subversive Mental Health ETF (SANE), BTD Capital Fund (DIP), Formidable Fortress ETF (KONG), Nuveen ESG Mid-Cap Growth ETF (NUMG), Goldman Sachs Future Health Care Equity ETF (GDOC), BlackRock Future Health ETF (BMED), Fidelity Disruptive Medicine ETF (FMED) and First Trust Indxx Medical Devices ETF (MDEV).

West Pharmaceutical Services (NYSE:WST) pays an annual dividend of $0.76 per share and currently has a dividend yield of 0.20%. The company has been increasing its dividend for 30 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 11.08%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, WST will have a dividend payout ratio of 8.65% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for WST.

West Pharmaceutical Services issued an update on its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $7.65-$7.80 for the period, compared to the consensus EPS estimate of $7.71. The company issued revenue guidance of $2.97 billion-$3.00 billion, compared to the consensus revenue estimate of $2.98 billion.

107 employees have rated West Pharmaceutical Services Chief Executive Officer Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among the company's employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.79%), Bank of New York Mellon Corp (4.66%), State Street Corp (4.43%), Franklin Resources Inc. (2.94%), Geode Capital Management LLC (2.15%) and Durable Capital Partners LP (1.73%). Insiders that own company stock include Annette F Favorite, Bernard Birkett, Charles Witherspoon, Cindy Reiss-Clark, Eric Mark Green, George Lloyd Miller, Patrick J Zenner, Quintin J Lai, Silji Abraham and Thomas W Hofmann.
View institutional ownership trends.

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WST stock can currently be purchased for approximately $379.23.

West Pharmaceutical Services (NYSE:WST) has a market capitalization of $28.01 billion and generates $2.89 billion in revenue each year. The medical instruments supplier earns $585.90 million in net income (profit) each year or $6.86 on an earnings per share basis.

The company employs 13,550 workers across the globe.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The official website for the company is www.westpharma.com. The medical instruments supplier can be reached via phone at (610) 594-2900, via email at quintin.lai@westpharma.com, or via fax at 800-345-9800.